Our goal at the National Kidney Foundation (NKF) is to transform the process in which the healthcare community views patients from passive, to active and engaged partners in the healthcare decision making process, and centers them as key collaborators in research and in policies which directly impact them.
Latest Patient Engagement Updates
9/21/18 — The National Kidney Foundation has issued comments to the Department of Health and Human Services in response to their RFI on KidneyX. Read the comments (pdf).
09/10/18— The National Kidney Foundation has issued recommendations on how the FDA can strengthen its first, in a series of four, Patient-Focused Drug Development (PFDD) draft guidance document. This document underscores FDA’s commitment to patient engagement in medical product development to include both pharmaceuticals and devices. Through this and future PFDD guidance, the FDA is establishing a road map for how industry, patients, patient advocacy organizations, and other stakeholders can submit and use patient experience for medical product development. The National Kidney Foundation is hopeful that, with this guidance, patient-focused medical product development will become better incorporated into FDA decision making and the development of new therapies holistically, not as a standalone activity. Read the comments (pdf).
9/22/17 — The National Kidney Foundation submitted comments to CMS on the 2018 proposed changes to the Physician fee Schedule include changes to the Medicare Diabetes Prevention Program. Read the final comments (pdf).
6/12/17 — NKF submitted comments to the Food and Drug Administration (FDA) regarding its consideration of the establishment of an Office of Patient Affairs. Read the full NKF Comments (pdf).